All News

gout.podagra.jpg

Pegloticase in Severe Refractory Gout

d Olga Petryna, MD

Listen as Dr. Petryna reviews abstracts #0683 (Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate) and #0677 (A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study) from the 2020 ACR meeting. 

Read Article
blackboard chalkboard

SpA: Etiology to Diagnosis to Treatment - An Abstract Roundup

d Robert Chao, MD

Here's a review of ten abstracts and presentations on spondyloarthritis encompassing a wide range of topics from etiology to diagnosis to treatment.  

Read Article
guidelines.recommendations.jpg

New ACR RA Guidelines and Practice Changing Abstracts: RA Panel

d Jonathan Kay, MD

Dr. Jonathan Kay leads an international panel discussion on the new ACR RA guidelines and several practice-changing abstracts presented at the 2020 ACR meeting. Panelists include Dr. Kathryn Dao, Dr. Eric Dein, Dr. Meral El Ramahi, Dr. Richard Conway and Dr. Sheila Reyes.

Read Article
#BestACR20Tweets RT @ejdein1 : #ACR20 Abs#L11. Efficacy of TOFA vs PBO in AS. At week 16, %ASAS20 responders 56% v 29% PBO; %ASAS40 40% vs 12%. @RheumNow #ACRBest https://t.co/knduk3l6xV https://t.co/SNommxn1jA

Links:

Dr. John Cush RheumNow ( View Tweet)
SKIPPAIN Trial: Dr. Sheila Reyes ( @RHEUMarampa) reviews abstract #0899 presented at #ACR20. https://t.co/yoQ8MEH2Br https://t.co/1uRKEp88le

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @ejdein1 : Worth checking out the #ACR20 image competition. Here's an image of cerebral toxoplasmosis during ADA treatment for RA https://t.co/JH07pMjvRe https://t.co/H9LHwiw4xL

Links:

Dr. John Cush RheumNow ( View Tweet)
Auckland-based rheumatologist Dr. Nicola Dalbeth discusses improving responses to the use of Pegloticase, including abstracts #0677 and #0952 presented at #ACR20. https://t.co/xeiMYLZEQa https://t.co/a4RJ6BrNgn

Links:

Dr. John Cush RheumNow ( View Tweet)
Vaccination with Shingrix: Does it work for patients on JAKi? #ACR20 https://t.co/PLWn3SshcI https://t.co/APBcfP1zlH

Links:

Dr. John Cush RheumNow ( View Tweet)
Nomenclature, Uveitis and Other Spondyloarthritis Features with Dr. Lianne Gensler #ACR20 https://t.co/zql7iySXOA https://t.co/PY9k108QTc

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @doctorRBC : Tocilizumab NOT effective in preventing mechanical ventilation or death in moderately ill COVID-19 pts. Double-blind, Placebo, RCT (n=243) @RheumNow #ACR20 Abs#L07 #ACRbest https://t.co/Gi5FpodeKf https://t.co/bTk8n7dNni

Links:

Dr. John Cush RheumNow ( View Tweet)
Warfarin and Risk of Hip and Knee Replacements with Dr. Mrinalini Dey ( @DrMiniDey) #ACR20. https://t.co/znTxIx1QQZ https://t.co/elQlChwr0N

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @KDAO2011 : The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF weren't allowed in this study; still cautious prescribing febuxostat to pts who have severe CVD until we have more data. https://t.co/eyl2kOjEEU https://t.co/qoQDgRifFg

Links:

Dr. John Cush RheumNow ( View Tweet)
Let us know your thoughts on our article titled "Undifferentiated Autoinflammatory Syndrome Called VEXAS" https://t.co/afNK3UuZef #ACR20 https://t.co/fp2sX9w894

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @synovialjoints : Can we find Axial Spa (FaxSpa) using social media? This study used an online screening tool (A-tool) on social media in patients with back pain. 42% had a positive screen and referred for review @RheumNow #ACR20 Abstr#1894

Dr. John Cush RheumNow ( View Tweet)

Dr. Kathryn Dao ( @KDAO2011) reviews abstract #0533 presented at #ACR20 on male osteoporosis. https://t.co/Z0NLcJzslV https://t.co/SSoIA7Eetg

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @DrMiniDey : Late breaking: in older #rheumatoidarthritis patients, those taking MTX have 2x risk of #VTE compared to those on HCQ. Important to consider #thromboembolic risk factors when starting new RA treatment. Abs#2000 #ACR20 https://t.co/lMYlXgaHyE https://t.co/0Fdone9yb3

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @drdavidliew : Mavrilimumab (anti-GM-CSF) in GCA, phase 2 GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying?? PNL induction then enrol+PNL taper GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62% ABSTL06 https://t.co/xxjd2lTSUe https://t.co/uuBOnbk6Ab

Links:

Dr. John Cush RheumNow ( View Tweet)
Did you know we have podcast? Search Rheum Now on Apple/Android or listen directly through the link below. https://t.co/wjBWCrKL34 https://t.co/yhZ2wyujA0

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @synovialjoints : The majority of patients with axSpA were able to use an axSpA smartphone app. recording BASDAI, BASFI 2 weekly. Current disease activity influence adherence to reporting @RheumNow #ACR20 Abstr#1890

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @ejdein1:Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w): 2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20

Dr. John Cush RheumNow ( View Tweet)

×